No Data
No Data
JMP Securities Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $17
Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating
Acrivon Therapeutics To Highlight Differentiated Drug Discovery Capabilities With Its Generative Phosphoproteomics AP3 Platform And Program Updates From The Phase 2b Study Of ACR-368 And Phase 1 Study Of ACR-2316, Via Webcast On March 25, 2025 At 4:00...
Express News | Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical Acr-368 and Acr-2316 Program Updates
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Acrivon Therapeutics Names Adam Levy as CFO
Unlock the Full List